Maprotilina Ratiopharm

Maprotiline Hydrochloride, the active ingredient in Maprotilina Ratiopharm, is a tetracyclic antidepressant presented as an oral formulation for oral use. It is prescribed for the treatment of depressive disorders in adult patients.

GNH USA supplies Maprotilina Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and other healthcare facilities worldwide.

Maprotiline, a tetracyclic antidepressant that modulates norepinephrine pathways, is indicated for: - Major depressive disorder: reduces depressive symptoms in adults. - Depressive episodes with melancholia: improves mood, sleep and energy levels. - Depressive disorder with anxiety features: alleviates anxiety accompanying depression.

Common Side Effects: - Dry mouth: reduced salivary flow causing discomfort. - Drowsiness or sedation: increased sleepiness, especially at treatment initiation. - Constipation: slowed gastrointestinal motility. - Weight gain: modest increase in body weight over time. - Dizziness: sensation of light‑headedness or imbalance. - Blurred vision: temporary visual disturbances.

Serious or Rare Side Effects: - Cardiac arrhythmias: irregular heart rhythms requiring medical attention. - Seizures: risk of convulsive episodes, particularly at high doses. - Severe hypotension: marked drop in blood pressure causing faintness. - Hepatotoxicity: liver enzyme elevations or injury. - Agranulocytosis: dangerously low white‑blood‑cell count. - Neuroleptic malignant‑like syndrome: rare but life‑threatening reaction with fever and muscle rigidity.

Before initiating therapy, consider the following precautions: - Cardiac assessment: evaluate history of heart disease or arrhythmias. - Liver function: monitor hepatic enzymes in patients with hepatic impairment. - Renal function: adjust use in severe renal insufficiency. - Concomitant CNS depressants: avoid excessive sedation when combined with alcohol or other sedatives. - Elderly patients: start at low dose and monitor for orthostatic hypotension. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Maprotiline may interact with several drug classes. Clinicians should review patient medication lists carefully. Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis or serotonin syndrome. - Other norepinephrine reuptake inhibitors: additive cardiovascular effects. - QT‑prolonging agents: increased risk of arrhythmias. Moderate Interactions (Monitor Closely):\n- CNS depressants (benzodiazepines, opioids): enhanced sedation. - Anticholinergic drugs: heightened anticholinergic burden. - CYP2D6 substrates: altered metabolism may require dose adjustment.